Literature DB >> 5631047

Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy.

C Naranjo, A T Shulgin, T Sargent.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5631047     DOI: 10.1159/000137100

Source DB:  PubMed          Journal:  Med Pharmacol Exp Int J Exp Med        ISSN: 0543-3002


× No keyword cloud information.
  7 in total

1.  Experience with MDA.

Authors:  R N Richards
Journal:  Can Med Assoc J       Date:  1972-02-05       Impact factor: 8.262

Review 2.  MDMA for the treatment of mood disorder: all talk no substance?

Authors:  Rachel Patel; Daniel Titheradge
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

3.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

4.  Drug discrimination studies with MDMA and amphetamine.

Authors:  R Oberlender; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 5.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

Review 6.  3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.

Authors:  Raúl López-Arnau; Jordi Camarasa; Marcel Lí Carbó; Núria Nadal-Gratacós; Pol Puigseslloses; María Espinosa-Velasco; Edurne Urquizu; Elena Escubedo; David Pubill
Journal:  Front Psychiatry       Date:  2022-10-03       Impact factor: 5.435

Review 7.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.